Onco360 Receives Approval to Dispense Zydelig

Currently serving as OncoMed Pharmaceutical Services’ Senior Vice President of Operation, Ellen Scharaga oversees dispensing operations as well as hiring and training of departmental personnel. From Melville, NY, Ellen Scharaga’s job accomplishments include gaining Joint Commission Accreditation for OncoMed facilities and reducing prescription processing time by nearly one-third.

Also known as Onco360, OncoMed is among the country’s fastest-expanding oncology pharmacies and clinical support service providers. Recently, Onco360 was chosen as one of the highly limited specialty pharmacies permitted to dispense the Zydelig (idelalisib) tablets, which are newly approved by the U.S. Food and Drug Administration (FDA).

Zydelig is now approved for the treatment of three types of B-cell blood cancers, which include relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and small lymphocytic lymphoma (SLL). Speaking about the company’s appointment to dispense Zydelig, Onco360’s Vice-Chairman Burt Zweigenhaft said, “I am very proud of the great people at Onco360. Selections such as this help validate the great job they do fulfilling the company’s patient-centric mission and values.”